No Detail Found!

Response to different conventional interferons in treatment of chronic hepatitis C

Author(s)
Waqaruddin Ahmed Pakistan Medical Research Centre, Jinnah Postgraduate Medical Centre, Karachi, Pakistan
Ambreen Arif Pakistan Medical Research Centre, Jinnah Postgraduate Medical Centre, Karachi, Pakistan
Ejaz Alam Pakistan Medical Research Centre, Jinnah Postgraduate Medical Centre, Karachi, Pakistan
Huma Qureshi Pakistan Medical Research Council, Islamabad, Pakistan
Abstract
Background: Sustained virological response to interferon therapy is a great challenge for patients of chronic Hepatitis C. Over 20 brands of interferons are available in the local market with each claiming over 80% response and a wide variation in the cost thus creating confusion for treating physicians as to which drug should be selected. Methods: Chronic Hepatitis C patients attending outpatients department of Pakistan Medical Research Centre JPMC from January 1998-December 2010 were evaluated. Complete blood count, liver function tests, serum proteins, HCV-RNA were done in all cases before starting therapy. Side effects were also noted. Results: Total of 851 cases received interferon 3 MIU three times a week for 6 months. There were 638 (75%) males and 213 (25%) females, mean age was 36.1±10.4 years. All were HCV-RNA positive prior to treatment, at the end of 6 months 666 (78.3%) became negative while 185 (21.7%) were non-responders with positive HCV RNA. End of treatment response (ETR) showed 84.7% with Bioferon (Argentina), 83.8% Hebron (Cuba), 82.2% INF (Argentina), 82.1% Ceron (China), 81% Viteron (Korea), 80.7% Leveron (Argentina), 81.5% Hepaferon, 79.1% Anferon (China), 77.4% Intron (Belgium), 75% Green alpha (Korea), 74% Roferon (Switzerland), 67.3% Uniferon (Lithuania), and 68.4% with others. Post-treatment 211 cases were lost to follow-up. In remaining 358/640 (55.9%) negative for HCV-RNA, at six months follow up, whereas 98 (15.3%) relapsed. Sustained virological response (SVR) Ceron 68.2%, Hebron 66.3%, Bioferon 65.2%, Leveron 60.5%, Intron 60.3%, Viteron 57%, Anferon 53.3%, Green alpha, Roferon, Hepaferon, and others 50%, INF 48.5% and Uniferon 41.9%. Average cost of these interferons was Rs. 6,000/month, except Hepaferon 5,000/month, Roferon 10,600/month. Conclusions: ETR ranged from 74-84.7% and SVR 41.9% to 68.2% and >60% SVR was observed with Ceron, Hebron, Bioferon, Leveron, Intron and were cost effective.
Publication Details
Page(s) 3-4
DOI DOI not available
Published Journal: Journal of Ayub Medical College, Volume: 24, Issue: 3--4, Year: 2012

Request the full text from PASTIC

Keywords
response, Conventional interferon, Chronic Hepatitis C.
0

Citations

0

Downloads

57

Views